Previous close | 5.95 |
Open | 5.84 |
Bid | 6.71 x 900 |
Ask | 6.80 x 1800 |
Day's range | 5.73 - 6.82 |
52-week range | 3.33 - 14.70 |
Volume | |
Avg. volume | 65,208 |
Market cap | 32.23M |
Beta (5Y monthly) | 1.88 |
PE ratio (TTM) | N/A |
EPS (TTM) | -36.59 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 29 Jan 2009 |
1y target est | N/A |
The9 Limited (Nasdaq: NCTY) ("The9"), an established Internet company, today announced that it signed a definitive share purchase agreement (the "Agreement") with WM Therapeutic Co., Ltd. ("WM Therapeutic"), a company operating Generative AI (GenAI) large language model (LLM) multi-dimensional and multi-omics digital precision medicine platform for brain disease, to purchase an additional 21.7% shares of WM Therapeutic by cash and issuance of The9's restricted shares. The9 had invested 8.3% shar
The9 Limited (Nasdaq: NCTY) ("The9"), an established Internet company, today announced that it signed a legally binding term sheet (the "Term Sheet") with Shenma Limited ("Shenma") to purchase 51% shares of Shenma by cash and issuance of The9's restricted shares. Pursuant to the Term Sheet, The9 will pay cash consideration of US$1 million and will issue restricted Class A ordinary shares to Shenma or its shareholders with the value of US$14.3 million. The value of each share will be determined b
The9 Limited (Nasdaq: NCTY) ("The9"), an established Internet company, today announced that it signed a legally binding term sheet (the "Term Sheet") with Zhejiang Fazhidao Information Technology Co., Ltd. ("Fazhidao") to purchase 19% shares of Fazhidao by cash and issuance of The9's restricted shares. The9 is also granted a purchase option to purchase up to 51% of the total shares of Fazhidao, based on a valuation calculated as 7 times of Fazhidao's audited annual profit after tax, provided tha